A Short Synthesis of Conformationally Constrained Unnatural Bicyclic Amino Acids Containing a Nitrogen Atom at the Ring Juncture: (9aR)- and (9aS)-Octahydropyrido[1,2-a]pyrazine-(3S)-carboxylic Acids (Opc)

Soon Mog So; Chang-Eun Yeom; Seong Mi Cho; Soo Young Choi; Young Keun Chung; B. Moon Kim

doi:10.1055/s-2008-1042762

LETTER

A Short Synthesis of Conformationally Constrained Unnatural Bicyclic Amino Acids Containing a Nitrogen Atom at the Ring Juncture: (9aR)- and (9aS)-Octahydropyrido[1,2-a]pyrazine-(3S)-carboxylic Acids (Opc)

Soon Mog So, Chang-Eun Yeom, Seong Mi Cho, Soo Young Choi, Young Keun Chung, B. Moon Kim*
Department of Chemistry, College of Natural Sciences, Seoul National University, Seoul 151-747, Korea
Fax: +82(2)8727505; e-Mail: kimbm@snu.ac.kr;

Abstract

All articles of this category

Abstract

A short and efficient route to conformationally constrained amino acid analogues, (9aR)- and (9aS)-octahydropyrido[1,2-a]pyrazine-(3S)-carboxylate (Opc) has been developed. The new bicyclic amino acid derivatives can be stored and utilized as a modular unit for the construction of unnatural oligopeptides using conventional peptide coupling methods.

Key words

conformationally constrained - unnatural amino acid - bicyclic - peptidomimetic - cyclic sulfamidate

Full Text

References

References and Notes

For a review, see:

1a Goodmann M. Ro S. In Burger’s Medicinal Chemistry and Drug Discovery Vol. 1: Wolff ME. John Wiley and Sons; New York: 1995. p.803-861

1b Gibson SE. Guillo N. Tozer MJ. Tetrahedron 1999, 55: 585

1c Hruby VJ. Acc. Chem. Res. 2001, 34: 389

For example, see:

2a Roberts NA. Martin JA. Kinchington D. Broadhurst AV. Craig JC. Duncan IB. Galpin SA. Handa BK. Kay J. Krohn A. Lambert RW. Merrett JH. Mills JS. Parkes KEB. Redshaw S. Ritchie AJ. Taylor DL. Thomas GJ. Machin PJ. Science 1990, 248: 358

2b Kalish VJ. Tetlock JH. Davies JF. Kaldor SW. Dressman BA. Reich S. Pino M. Nyugen D. Appelt K. Musick L. Wu B. Bioorg. Med. Chem. Lett. 1995, 5: 727

2c Ghosh AK. Hussain KA. Fidanze S. J. Org. Chem. 1997, 62: 6080

For example, see:

3a Hunt JT. Lee VG. Leftheris K. Seizinger B. Carboni J. Mabus J. Ricca C. Yan N. Manne V. J. Med. Chem. 1996, 39: 353

3b Georg GI. Harriman GB. Ali SM. Datta A. Hepperle M. Himes RH. Bioorg. Med. Chem. Lett. 1997, 5: 115

For example, see:

4a Bigge CF. Wu J. Malone TC. Taylor CP. Vartanian MG. Bioorg. Med. Chem. Lett. 1993, 3: 39

4b Ho B. Crider AM. Stables JP. Eur.
J. Med. Chem. 2001, 205

For example, see:

5a Thurieau C. Félétou M. Hennig P. Raimbaud E. Canet E. Fauchère J. J. Med. Chem. 1996, 39: 2095

5b Mavunkel BJ. Lu Z. Goehring RR. Lu S. Chakravarty S. Perumattam J. Novotny EA. Connolly M. Valentine H. Kyle DJ. J. Med. Chem. 1996, 39: 3169

6 For example, see: Shuman RT. Rothenberger RB. Campbell CS. Smith GF. Gifford-Moore DS. Gesellchen PD. J. Med. Chem. 1993, 36: 314

For example, see:

7a Klutchko S. Blankley CJ. Fleming RW. Hinkley JM. Werner AE. Nordin I. Holmes A. Hoefle ML. Cohen DM. J. Med. Chem. 1986, 29: 1953

7b Rosenkranz RP. Hayashi CM. Lakatos I. McClelland DL. Proc. West. Pharmacol. Soc. 1989, 32: 221

8 For example, see: Steinbaugh BA. Hamilton HW. Patt WC. Rapundalo ST. Batley BA. Lunney EA. Ryan MJ. Hicks GW. Bioorg. Med. Chem. Lett. 1994, 4: 2029

9 For example, see: Klutchko S. Hamby JM. Hodges JC. Bioorg. Med. Chem. Lett. 1994, 4: 57

10a Katritzky AR. Rachwal S. Rachwal B. Tetrahedron 1996, 52: 15031

10b Barbier D. Marazano C. Riche C. Das BC. Potier P. J. Org. Chem. 1998, 63: 1767

10c Mash EA. Williams LJ. Pfeiffer SS. Tetrahedron Lett. 1997, 38: 6977

10d Kametani T. The Total Synthesis of Isoquinoline Alkaloids, In The Total Synthesis of Natural Products Vol. 3: ApSimon J. John Wiley; New York: 1977. p.1-272

11a Kim BM. Bae SJ. So SM. Yoo HT. Chang SK. Lee JH. Kang JS. Org. Lett. 2001, 3: 2349

11b Kim BM. Vacca JP. Guare JP. Hanifin CM. Michelson SR. Darke PL. Zugay JA. Emini EA. Schleif W. Lin JH. Chen I.-W. Vastag K. Ostovic D. Anderson PS. Huff JR. Bioorg. Med. Chem. Lett. 1994, 4: 2273

11c Kim BM. G uare JP. Vacca JP. Michelson SR. Darke PL. Zugay JA. Emini EA. Schleif W. Lin JH. Chen I.-W. Vastag K. Anderson PS. Huff JR. Bioorg. Med. Chem. Lett. 1995, 5: 185

12a Kim BM, Graham SL, Shaw AW, de Solms J, and Ciccarone T. inventors; US 5,817,678.

12b Kim BM, Shaw AW, Graham SL, de Solms JS, and Ciccarone TM. inventors; EP 0862435.

13a Baldwin JE. Spivey AC. Schofield CJ. Tetrahedron: Asymmetry 1990, 1: 881

13b Ok D. Fisher MH. Wyvratt MJ. Meinke PT. Tetrahedron Lett. 1999, 40: 3831

13c Cohen SB. Halcomb RL. Org. Lett. 2001, 3: 405

13d Atfani M. Wei L. Lubell WD. Org. Lett. 2001, 3: 2965

13e Cohen SB. Halcomb RL. J. Am. Chem. Soc. 2002, 124: 2534

13f Nicolaou KC. Huang X. Snyder SA. Rao PB. Bella M. Reddy MV. Angew. Chem. Int. Ed. 2002, 41: 834

13g Posakony JJ. Grierson JR. Tewson TJ. J. Org. Chem. 2002, 67: 5164

13h Pound MK. Davies DL. Pilkington MPV. Sousa MM. Wallis JD. Tetrahedron Lett. 2002, 43: 1915

14a Kim BM. So SM. Tetrahedron Lett. 1998, 39: 5381

14b Kim BM. So SM. Tetrahedron Lett. 1999, 40: 7687

14c Kim BM. Bae SJ. So SM. Yoo HT. Chang SK. Lee JH. Kang JS. Org. Lett. 2001, 3: 2349

14d Kim BM. So SM. Choi HJ. Org. Lett. 2002, 4: 949

15a Baldwin JE. Adlington RM. Mellor LC. Tetrahedron 1994, 50: 5049

15b Augilera B. Mayoralas AF. Jaramillo C. Tetrahedron 1997, 53: 5863

15c Wel L. Lubell WD. Org. Lett. 2000, 2: 2595

16 Rodwell VW. Methods in Enzymology Part B, Vol. 17: Academic Press; New York: 1971. p.174

17 Henry JR. Marcin LR. McIntosh C. Scola PM. Harris GD. Weinreb SM. Tetrahedron Lett. 1989, 30: 5709

18a Pederson CJ. J. Am. Chem. Soc. 1967, 89: 7017

18b Alexander V. Chem. Rev. 1995, 95: 273

19a Sharpless KB. Kim BM. Tetrahedron Lett. 1989, 30: 655

19b Okada M. Tomioka K. Tetrahedron Lett. 1994, 35: 4585

20

CCDC #660993.

21

Characterization Data for Compound 16 [α]_D ²⁷ -15.0 (c 1.1, CHCl₃). ¹H NMR (300 MHz, CDCl₃):
δ = 0.03 (s, 6 H), 0.88 (s, 9 H), 1.28 (t, 3 H), 1.32-1.70 (m, 6 H), 2.23-2.45 (m, 1 H), 2.50-2.57 (m, 1 H), 2.64-2.76 (m, 3 H), 2.97-3.05 (m, 1 H), 3.38-3.51 (m, 2 H), 3.94 (ABq, J = 13.3 Hz, 2 H), 3.96-3.88 (m, 1 H), 4.26-4.32 (m, 2 H), 7.21-7.32 (m, 5 H). ¹³C NMR (75 MHz, CDCl₃): δ = -5.47, 14.28, 18.21, 22.16, 25.39, 25.84, 28.20, 51.06, 52.14, 56.96, 59.58, 60.34, 62.17, 63.70, 126.86, 128.16, 128.22, 139.85, 174.46. HRMS (CI): m/z calcd for C₂₃H₄₁N₂O₃Si
[M + H]⁺: 421.2886; found: 421.2884.

22

Characterization Data for Compound 17 [α]_D ²⁸ -4.1 (c 1.1, CHCl₃). ¹H NMR (300 MHz, CDCl₃): δ = 1.29 (t, 3 H), 1.37-1.71 (m, 6 H), 2.27-2.45 (m, 2 H), 2.57-2.64 (m, 1 H), 2.82-2.91 (m, 1 H), 2.98-3.05 (m, 1 H), 3.22 (br s, 2 H), 3.35-3.42 (m, 2 H), 3.67-3.76 (m, 1 H), 3.75 (ABq, J = 12.9, 2 H), 4.13-4.24 (m, 2 H), 7.22-7.32 (m, 5 H). ¹³C NMR (75 MHz, CDCl₃): δ = 14.25, 23.71, 23.86, 27.05, 52.47, 52.74, 54.38, 59.89, 60.92, 61.95, 63.07, 127.20, 128.35, 128.42, 139.03, 174.90. HRMS (CI): m/z calcd for C₁₈H₂₉N₂O₃ [M + H]⁺: 321.2178; found: 321.2176.

23

Characterization Data for Compound 19 [α]_D ²⁷ -10.5 (c 1.0, CHCl₃). ¹H NMR (300 MHz, CDCl₃):
δ = 1.12-1.29 (m, 2 H), 1.27 (t, 3 H), 1.34-1.41 (m, 1 H), 1.56-1.59 (m, 2 H), 1.65-1.68 (m, 1 H), 1.87-1.96 (m, 2 H), 2.38-2.48 (m, 2 H), 2.70-2.74 (m, 1 H), 2.90-2.97 (m, 1 H), 3.04-3.08 (m, 1 H), 3.40 (s, 1 H), 3.90 (ABq, J = 13.7, 2 H), 4.14-4.24 (m, 2 H), 7.20-7.31 (m, 5 H). ¹³C NMR (75 MHz, CDCl₃): δ = 14.78, 24.37, 25.96, 29.91, 53.41, 56.15, 58.27, 59.35, 60.25, 60.62, 61.85, 127.30, 128.65, 129.03, 139.75, 172.83. HRMS (CI): m/z calcd for C₁₈H₂₇N₂O₂ [M + H]⁺: 303.2072; found: 303.2073.

24

Characterization Data for Compound 22 [α]_D ¹¹ -31.3 (c 1.00, CHCl₃).¹H NMR (300 MHz, CDCl₃):
δ = 1.11-1.96 (m, 17 H), 2.24-2.31 (m, 1 H), 2.70-2.88 (m, 2 H), 3.17-3.24 (m, 1 H), 3.62 (d, J = 3.2 Hz, 0.25 H), 3.66 (d, J = 3.2 Hz, 0.25 H), 3.74-3.80 (m, 3.5 H), 4.53 (d, J = 4 Hz, 0.5 H), 4.70 (d, J = 4 Hz, 0.5 H). ¹³C NMR (75 MHz, CDCl₃): δ = 24.02, 24.07, 25.67, 28.64, 28.73, 29.54, 29.56, 46.87, 47.84, 52.58, 54.38, 55.65, 55.81, 55.93, 56.17, 60.70, 60.72, 80.55, 80.60, 155.54, 155.96, 171.68, 171.98. HRMS-FAB: m/z calcd for C₁₅H₂₇N₂O₄ [M + H]⁺: 299.1971; found: 299.1970.

25

Characterization Data for Compound 23 [α]_D ¹¹ +23.9 (c 1.00, CHCl₃). ¹H NMR (300 MHz, CDCl₃): δ = 1.12-1.28 (m, 2 H), 1.51-1.61 (m, 3 H), 1.72-1.98 (m, 3 H), 2.03 (s, 0.7 H), 2.14 (s, 2.3 H), 2.24 (dd, 0.75 H), 2.33 (dd, 0.25 H), 2.49-2.61 (m, 0.25 H), 2.77-2.80 (m, 0.75 H), 3.09-3.18 (m, 0.9 H), 3.24-3.38 (m, 1.2 H), 3.43-3.54 (m, 0.9 H), 3.75 (s, 2.3 H), 3.79 (s, 0.7 H), 4.22-4.23 (m, 0.08 H), 4.27-4.28 (m, 0.08 H), 4.34-4.37 (m, 0.14 H), 5.17-5.19 (m, 0.7 H). ¹³C NMR (75 MHz, CDCl₃): δ = 21.52, 21.81, 23.98, 25.58, 25.67, 29.55, 29.62, 45.07, 49.88, 52.51, 52.76, 53.12, 55.72, 55.82, 56.04, 56.43, 57.57, 60.63, 60.98, 170.79, 171.01, 171.22. HRMS-FAB: m/z calcd for C₁₂H₂₁N₂O₃ [M + H]⁺: 241.1552; found: 241.1558.

26

Characterization Data for Compound 24 [α]_D ¹¹ -59.2 (c 1.00, CHCl₃). ¹H NMR (300 MHz, CDCl₃):
δ = 1.03-1.31 (m, 2 H), 1.41-2.01 (m, 6 H), 2.12 (s, 1.2 H), 2.23 (m, 1.8 H), 2.34-2.52 (m, 2 H), 2.78-2.86 (m, 1 H), 3.03-3.15 (m, 1 H), 3.29-3.33 (m, 0.4 H), 3.44-3.48 (m, 0.4 H), 3.71-3.78 (m, 0.2 H), 4.32-4.55 (m, 2.6 H), 5.18-5.20 (m, 0.4 H), 7.05 (s, 0.4 H), 7.26-7.69 (m, 5 H), 8.46 (m, 0.6 H). ¹³C NMR (75 MHz, CDCl₃): δ = 21.89, 21.96, 23.81, 23.94, 25.62, 25.89, 29.62, 29.74, 43.78, 43.83, 44.07, 50.02, 52.95, 55.26, 55.52, 55.735, 55.89, 57.70, 60.75, 61.26, 126.29, 127.75, 127.88, 127.91, 128.22, 129.050, 129.14, 138.39, 138.70, 169.76, 170.05, 170.51, 170.91. HRMS-FAB: m/z calcd for C₁₈H₂₆N₃O₂ [M + H]⁺: 316.2025; found: 316.2026.